Stimulating
angiogenesis during wound healing continues to present
a significant clinical challenge, given the limitations of current
strategies to maintain therapeutic doses of growth factors and endothelial
cell efficacy. Incorporating a balance of specific cues to encourage
endothelial cell engraftment and cytokines to facilitate angiogenesis
is necessary for blood vessel growth in the proinflammatory wound
environment. Here, we incorporate a previously designed peptide (LXW7)
capable of binding to the αvβ3 integrin of endothelial
cells with a dermatan sulfate glycosaminoglycan backbone grafted with
collagen-binding peptides (SILY). By exploiting αvβ3 integrin-mediated
VEGF signaling, we propose an alternative strategy to overcome shortcomings
of traditional growth factor therapy while homing the peptide to the
wound bed. In this study, we describe the synthesis and optimization
of LXW7–DS–SILY (LDS) variants and evaluate their angiogenic
potential in vitro and in vivo. LDS displayed binding to collagen
and endothelial cells. In vitro, the LDS variant
with six LXW7 peptides increased endothelial cell proliferation, migration,
and tubule formation through increased VEGFR2 phosphorylation compared
to nontreated controls. In an in vivo chick chorioallantoic membrane
assay, LDS laden collagen hydrogels increased blood vessel formation
by 43% in comparison to the organism matched blank hydrogels. Overall,
these findings demonstrate the potential of a robust targeted glycan
therapeutic for promoting angiogenesis during wound healing.